Suppr超能文献

A short overview of dual targeting HDAC inhibitors.

作者信息

Liu Wen-Bo, Song Jian, Zhang Sai-Yang

机构信息

School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.

State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, China.

出版信息

Future Med Chem. 2025 Jan;17(1):5-7. doi: 10.1080/17568919.2024.2437975. Epub 2024 Dec 8.

Abstract
摘要

相似文献

1
A short overview of dual targeting HDAC inhibitors.
Future Med Chem. 2025 Jan;17(1):5-7. doi: 10.1080/17568919.2024.2437975. Epub 2024 Dec 8.
4
Overview of class I HDAC modulators: Inhibitors and degraders.
Eur J Med Chem. 2024 Oct 5;276:116696. doi: 10.1016/j.ejmech.2024.116696. Epub 2024 Jul 30.
5
Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer.
ACS Omega. 2023 May 1;8(19):16532-16544. doi: 10.1021/acsomega.3c00222. eCollection 2023 May 16.
6
Inhibition of class IIa HDACs reduces mutant HTT aggregation by affecting RNA stability.
Front Mol Neurosci. 2025 Jun 18;18:1579194. doi: 10.3389/fnmol.2025.1579194. eCollection 2025.
7
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors.
Pharmaceuticals (Basel). 2025 Feb 27;18(3):341. doi: 10.3390/ph18030341.
8
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
Eur J Med Chem. 2023 Dec 5;261:115800. doi: 10.1016/j.ejmech.2023.115800. Epub 2023 Sep 9.
9
A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.
EMBO Mol Med. 2015 Apr;7(4):438-49. doi: 10.15252/emmm.201404580.
10
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Eur J Med Chem. 2020 Dec 15;208:112831. doi: 10.1016/j.ejmech.2020.112831. Epub 2020 Sep 12.

本文引用的文献

1
2
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.
Eur J Med Chem. 2024 Sep 5;275:116571. doi: 10.1016/j.ejmech.2024.116571. Epub 2024 Jun 6.
3
Advances in targeting histone deacetylase for treatment of solid tumors.
J Hematol Oncol. 2024 May 31;17(1):37. doi: 10.1186/s13045-024-01551-8.
4
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations.
Acta Pharmacol Sin. 2024 Jun;45(6):1305-1315. doi: 10.1038/s41401-024-01236-5. Epub 2024 Feb 21.
5
Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2.
Drug Resist Updat. 2023 Nov;71:101011. doi: 10.1016/j.drup.2023.101011. Epub 2023 Oct 10.
6
The application of PROTAC in HDAC.
Eur J Med Chem. 2023 Nov 15;260:115746. doi: 10.1016/j.ejmech.2023.115746. Epub 2023 Aug 19.
7
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy.
Eur J Med Chem. 2023 Nov 5;259:115673. doi: 10.1016/j.ejmech.2023.115673. Epub 2023 Jul 20.
8
Targeting histone deacetylases for cancer therapy: Trends and challenges.
Acta Pharm Sin B. 2023 Jun;13(6):2425-2463. doi: 10.1016/j.apsb.2023.02.007. Epub 2023 Feb 18.
10
Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties.
J Med Chem. 2022 Dec 22;65(24):16313-16337. doi: 10.1021/acs.jmedchem.2c01132. Epub 2022 Nov 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验